Page 2 - Aurobindo Pharma Ltd News

Aurobindo Pharma Q1 results: Profit drops 10% to ₹824 crore on US sales

Aurobindo Pharma on Monday reported a 10 per cent decline in its consolidated net profit to Rs 824 crore for the June quarter, hit by dip in sales in the US and API business vertical. The Hyderabad-based drug maker posted a net profit of Rs 918 crore for the April-June quarter of last fiscal. Revenue from operations increased to Rs 7,868 crore for the June quarter as against Rs 7,567 crore in the year-ago period, Aurobindo Pharma said in a regulatory filing. "We started the year steadily, with our European business maintaining strong growth momentum and our core US business showing resilience despite temporary challenges from destocking and seasonal dynamics," K Nithyananda Reddy, Vice-Chairman and Managing Director of the company said. The company's disciplined execution, operational initiatives, and recent US acquisition strengthens commercial footprint and accelerates growth potential, he added. The board of directors at its meeting held on Monday has approved the payment of ..

Q1 results today: Shree Cement, Aurobindo Pharma, DLF, 103 others on Aug 4

Q1 FY26 company results, Aug 4: Marico, Aditya Birla Capital, Ather Energy, Bosch, Delta Corp, Siemens Energy India, Godfrey Phillips, and Inox India will release their April-June quarter report

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Trump on Wednesday called India's tariffs on US exports among the highest in the world, with the most strenuous non-monetary trade barriers of any country, in a post on Truth Social

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Aurobindo Pharma on Tuesday said it will manufacture and supply the long-acting injectable HIV treatment cabotegravir across 133 countries. The Hyderabad-based drugmaker has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare, the company said in a statement. The agreement allows Aurobindo to manufacture and supply the long-acting injectable HIV treatment across 133 countries, including several low and middle-income markets, it added. This update now includes long-acting cabotegravir (CAB LA) for HIV treatment, in addition to its earlier use for prevention only. The treatment offers an alternative to daily pills, allowing patients to receive just one injection every one or two months. "We are privileged to be part of the sub-license expansion from MPP and ViiV to develop, manufacture, and distribute generic CAB LA in select markets for the treatment of HIV-1, in addition to t

Aurobindo Pharma recalls over 4,600 bottles of painkiller in US market

The drug, Acetaminophen Tablets (325 mg), is being recalled due to manufacturing deviations from Current Good Manufacturing Practices, following complaints of brown tablet discolouration